• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

ImmuneRegen(R) BioSciences Confirms Adult Stem Cell Activity of Homspera(R) in Human Bone Marrow

Posted on: Monday, 9 June 2008, 06:00 CDT

ImmuneRegen(R) BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), announces additional study results that confirm the effects of its compound Homspera(R) in stimulating the development of human adult stem cells. The results, also found in earlier studies, document Homspera's ability to enhance formation of early-stage blood cells from adult hematopoietic (blood-forming) stem cells.

The studies performed at HemoGenix were repeated with cells isolated from multiple human bone marrow donors to account for donor variability. As expected, Homspera stimulated stem cell differentiation of both myeloid precursors (red blood cells, platelets and granulocytic white blood cells) and lymphoid precursors (T and B cells). The results are further evidence of Homspera's potential use to stimulate the replacement of blood cells and strengthen the human immune system, a critical concern for individuals fighting influenza and other illnesses or undergoing chemotherapy. Additional research and studies are underway to confirm the viability of the commercial use of Homspera for such purposes.

"Importantly, we have consistently observed a role for Homspera in enhancing granulocyte and monocyte precursor cells, which, along with B cells and T cells (the lymphocytes), make up the infection-fighting white cells of the immune system. Recall that Homspera is able to increase white blood cells in small animals whose immune system has been compromised by radiation," stated Kasey Benson, Ph.D., ImmuneRegen's scientific director.

"These confirmatory findings not only meet certain internal milestones, they also deepen our understanding of our drug candidate and position the company to confidently take the next step in assessing potential uses for Homspera in counteracting myelosuppression resulting from radiation, disease or drug-related side effects," stated Michael Wilhelm, ImmuneRegen CEO.

About HemoGenix, Inc.

HemoGenix was the first company to provide a fully standardized ATP-based, in vitro bioluminescence assay system designed specifically as an alternative to, and in most cases a replacement for, the colony-forming cell (CFC) assay used to detect stem and progenitor cells of the blood-forming system. Since its founding in 2000, HemoGenix has developed its own portfolio of proprietary assays for basic research, toxicity, safety and risk assessment for the biopharmaceutical and environmental arenas and quality control assays for stem cell transplantation processing laboratories. HemoGenix produces and sells its assay platforms directly or through its distributors worldwide.

About ImmuneRegen BioSciences, Inc.

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), is a development-stage biotechnology company focused on the research, development and licensing of Homspera(R), an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, Lovelace Respiratory Research Institute, UC Berkeley, HemoGenix and Virion Systems, Inc. For more information, please visit the company's website at www.immuneregen.com.

Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended March 31, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.

Source: Business Wire

More News in this Category